KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Inventory (2018 - 2025)

Historic Inventory for Alnylam Pharmaceuticals (ALNY) over the last 8 years, with Q3 2025 value amounting to $75.4 million.

  • Alnylam Pharmaceuticals' Inventory fell 79.49% to $75.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.4 million, marking a year-over-year decrease of 79.49%. This contributed to the annual value of $78.5 million for FY2024, which is 1193.21% down from last year.
  • Alnylam Pharmaceuticals' Inventory amounted to $75.4 million in Q3 2025, which was down 79.49% from $71.7 million recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Inventory registered a high of $131.9 million during Q1 2023, and its lowest value of $65.6 million during Q1 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' median Inventory value was $86.4 million (recorded in 2021), while the average stood at $90.4 million.
  • The largest annual percentage gain for Alnylam Pharmaceuticals' Inventory in the last 5 years was 6796.45% (2023), contrasted with its biggest fall of 3087.42% (2023).
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Inventory stood at $86.4 million in 2021, then soared by 49.33% to $129.0 million in 2022, then tumbled by 30.87% to $89.1 million in 2023, then decreased by 11.93% to $78.5 million in 2024, then fell by 3.98% to $75.4 million in 2025.
  • Its last three reported values are $75.4 million in Q3 2025, $71.7 million for Q2 2025, and $65.6 million during Q1 2025.